勘误：“PRMT6通过触发6PGD/ENO1介导的细胞代谢促进肺癌的肿瘤发生和顺铂反应”一文的作者更正[《中国药理学报B》13 (2023) 157 - 173]。
Erratum: Author correction to "PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD/ENO1 mediated cell metabolism" [Acta Pharm Sin B 13 (2023) 157-173].
作者信息
Sun Mingming, Li Leilei, Niu Yujia, Wang Yingzhi, Yan Qi, Xie Fei, Qiao Yaya, Song Jiaqi, Sun Huanran, Li Zhen, Lai Sizhen, Chang Hongkai, Zhang Han, Wang Jiyan, Yang Chenxin, Zhao Huifang, Tan Junzhen, Li Yanping, Liu Shuangping, Lu Bin, Liu Min, Kong Guangyao, Zhao Yujun, Zhang Chunze, Lin Shu-Hai, Luo Cheng, Zhang Shuai, Shan Changliang
机构信息
State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300350, China.
Biomedical Translational Research Institute, Jinan University, Guangzhou 510632, China.
出版信息
Acta Pharm Sin B. 2025 Apr;15(4):2297-2299. doi: 10.1016/j.apsb.2025.02.006. Epub 2025 Feb 12.
Abstract
[This corrects the article DOI: 10.1016/j.apsb.2022.05.019.].
摘要
[本文更正了文章的数字对象标识符：10.1016/j.apsb.2022.05.019。]
相似文献
1
Erratum: Author correction to "PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD/ENO1 mediated cell metabolism" [Acta Pharm Sin B 13 (2023) 157-173].勘误：“PRMT6通过触发6PGD/ENO1介导的细胞代谢促进肺癌的肿瘤发生和顺铂反应”一文的作者更正[《中国药理学报B》13 (2023) 157 - 173]。
Acta Pharm Sin B. 2025 Apr;15(4):2297-2299. doi: 10.1016/j.apsb.2025.02.006. Epub 2025 Feb 12.
2
PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD/ENO1 mediated cell metabolism.蛋白质精氨酸甲基转移酶6（PRMT6）通过触发6-磷酸葡萄糖脱氢酶（6PGD）/烯醇化酶1（ENO1）介导的细胞代谢促进肺癌的致瘤性和顺铂反应。
Acta Pharm Sin B. 2023 Jan;13(1):157-173. doi: 10.1016/j.apsb.2022.05.019. Epub 2022 May 25.
3
Erratum: Author correction to 'Pharmacologically targeting molecular motor promotes mitochondrial fission for anti-cancer' [Acta Pharm Sin B 11 (2021) 1853-1866].勘误：“Pharmacologically targeting molecular motor promotes mitochondrial fission for anti-cancer” [《中国药理学报B》11 (2021) 1853-1866]的作者更正。
Acta Pharm Sin B. 2024 May;14(5):2358. doi: 10.1016/j.apsb.2024.02.013. Epub 2024 Feb 21.
4
Erratum: Author correction to "Sphingosine-1-phosphate, a novel TREM2 ligand, promotes microglial phagocytosis to protect against ischemic brain injury" [Acta Pharm Sin B 12 (2022) 1885-1898].勘误：对“Sphingosine-1-phosphate, a novel TREM2 ligand, promotes microglial phagocytosis to protect against ischemic brain injury”[《中国药理学通报》12 (2022) 1885 - 1898]的作者更正。
Acta Pharm Sin B. 2025 May;15(5):2813-2814. doi: 10.1016/j.apsb.2025.02.032. Epub 2025 Feb 25.
5
Erratum: Author correction to "Generation of Gal-enhanced bifunctional tumor vaccine" [Acta Pharm Sin B 12 (2022) 3177-3186].勘误：“Gal增强型双功能肿瘤疫苗的生成”[《中国药理学通报》12 (2022) 3177 - 3186]的作者更正。
Acta Pharm Sin B. 2025 Feb;15(2):1207. doi: 10.1016/j.apsb.2024.11.021. Epub 2024 Nov 29.
6
Erratum: Author correction to 'Discovery of the radio-protecting effect of ecliptae herba, its constituents and targeting p53-mediated apoptosis and ' [Acta Pharm Sin B 13 (2023) 1216-1230].勘误：《墨旱莲及其成分的辐射防护作用与靶向p53介导的细胞凋亡》的作者更正 [《中国药理学通报》13 (2023) 1216 - 1230] 。
Acta Pharm Sin B. 2023 Jun;13(6):2815-2816. doi: 10.1016/j.apsb.2023.03.026. Epub 2023 Mar 31.
7
Erratum: Author correction to "The neuroprotective effect of traditional Chinese medicinal plants-A critical review" [Acta Pharm Sin B 13 (2023) 3208-3237].勘误：《中药的神经保护作用——综述》[《药学学报B》13 (2023) 3208 - 3237]的作者更正。
Acta Pharm Sin B. 2025 Apr;15(4):2300. doi: 10.1016/j.apsb.2024.12.002. Epub 2024 Dec 3.
8
Erratum: Author correction to 'FGF4 protects the liver from immune-mediated injury by activating CaMKK-PINK1 signal pathway to inhibit hepatocellular apoptosis' [Acta Pharm Sin B 14 (2024) 1605-1623].勘误：对“FGF4通过激活CaMKK-PINK1信号通路抑制肝细胞凋亡从而保护肝脏免受免疫介导损伤”一文的作者更正[《药学学报B》14 (2024) 1605-1623]。
Acta Pharm Sin B. 2024 Jun;14(6):2791-2793. doi: 10.1016/j.apsb.2024.04.008. Epub 2024 Apr 9.
9
Erratum: Author correction to "SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade" [Acta Pharm Sin B 9 (2019) 304-315].勘误：“SHP2抑制引发抗肿瘤免疫并与PD-1阻断协同作用”[《中国药理学通报》9 (2019) 304 - 315]的作者更正。
Acta Pharm Sin B. 2025 May;15(5):2810-2812. doi: 10.1016/j.apsb.2024.12.023. Epub 2024 Dec 23.
10
Erratum: Author correction to "TMEM16A inhibits angiotensin II-induced basilar artery smooth muscle cell migration in a WNK1-dependent manner" [Acta Pharm Sin B 11(12) (2021) 3994-4007].勘误：“TMEM16A以WNK1依赖的方式抑制血管紧张素II诱导的基底动脉平滑肌细胞迁移”[《中国药理学报B》11(12)(2021)3994 - 4007]的作者更正。
Acta Pharm Sin B. 2023 Mar;13(3):1340-1343. doi: 10.1016/j.apsb.2023.01.001. Epub 2023 Feb 2.
Zotero 插件